[go: up one dir, main page]

WO2007047577A3 - Use of calcitonin-related peptide (cgrp) antagonists or release inhibitors for the treatment of sleep-related breathing disorders - Google Patents

Use of calcitonin-related peptide (cgrp) antagonists or release inhibitors for the treatment of sleep-related breathing disorders Download PDF

Info

Publication number
WO2007047577A3
WO2007047577A3 PCT/US2006/040364 US2006040364W WO2007047577A3 WO 2007047577 A3 WO2007047577 A3 WO 2007047577A3 US 2006040364 W US2006040364 W US 2006040364W WO 2007047577 A3 WO2007047577 A3 WO 2007047577A3
Authority
WO
WIPO (PCT)
Prior art keywords
cgrp
antagonists
sleep
calcitonin
breathing disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/040364
Other languages
French (fr)
Other versions
WO2007047577A2 (en
Inventor
David W Carley
Miodrag Radulovacki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois at Urbana Champaign
University of Illinois System
Original Assignee
University of Illinois at Urbana Champaign
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois at Urbana Champaign, University of Illinois System filed Critical University of Illinois at Urbana Champaign
Publication of WO2007047577A2 publication Critical patent/WO2007047577A2/en
Publication of WO2007047577A3 publication Critical patent/WO2007047577A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention is directed to methods for preventing or ameliorating sleep-related breathing disorders. The method comprises administration to a patient in need thereof an effective dose of one or more calcitonin gene-related peptide (CGRP) receptor antagonists or release inhibitors. The CGRP receptor antagonist or combination of CGRP receptor antagonists can be administered in conjunction with one or more serotonin receptor agonists, one or more cannabinoid receptor agonists, one or more serotonin reuptake inhibitors, a combination of reuptake inhibitors, other agents, or any combination of the foregoing.
PCT/US2006/040364 2005-10-14 2006-10-13 Use of calcitonin-related peptide (cgrp) antagonists or release inhibitors for the treatment of sleep-related breathing disorders Ceased WO2007047577A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72690005P 2005-10-14 2005-10-14
US60/726,900 2005-10-14

Publications (2)

Publication Number Publication Date
WO2007047577A2 WO2007047577A2 (en) 2007-04-26
WO2007047577A3 true WO2007047577A3 (en) 2007-07-12

Family

ID=37866260

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/040364 Ceased WO2007047577A2 (en) 2005-10-14 2006-10-13 Use of calcitonin-related peptide (cgrp) antagonists or release inhibitors for the treatment of sleep-related breathing disorders

Country Status (1)

Country Link
WO (1) WO2007047577A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2687141C (en) 2007-05-22 2014-04-01 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
WO2023177823A1 (en) * 2022-03-17 2023-09-21 Vasoceuticals, Inc. Combined use of individual compounds for treatment of chronic pain disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080903A1 (en) * 2001-04-06 2002-10-17 The Board Of Trustees Of The University Of Illinois Functional role for cannabinoids in autonomic stability during sleep
US6727242B2 (en) * 1998-02-27 2004-04-27 The Board Of Trustees Of The University Of Illinois Pharmacological treatment for sleep apnea

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727242B2 (en) * 1998-02-27 2004-04-27 The Board Of Trustees Of The University Of Illinois Pharmacological treatment for sleep apnea
WO2002080903A1 (en) * 2001-04-06 2002-10-17 The Board Of Trustees Of The University Of Illinois Functional role for cannabinoids in autonomic stability during sleep

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ARULMANI ET AL: "Calcitonin gene-related peptide and its role in migraine pathophysiology", EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 500, no. 1-3, 1 October 2004 (2004-10-01), pages 315 - 330, XP005480426, ISSN: 0014-2999 *
BAUMAN N M ET AL: "Effect of intravenous calcitonin gene-related peptide antagonist on the laryngeal chemoreflex in piglets.", OTOLARYNGOLOGY--HEAD AND NECK SURGERY : OFFICIAL JOURNAL OF AMERICAN ACADEMY OF OTOLARYNGOLOGY-HEAD AND NECK SURGERY JUL 1999, vol. 121, no. 1, July 1999 (1999-07-01), pages 1 - 6, XP002427117, ISSN: 0194-5998 *
FRIBERG D ET AL: "Abnormal afferent nerve endings in the soft palatal mucosa of sleep apnoics and habitual snorers", REGULATORY PEPTIDES, ELSEVIER SCIENCE BV, NL, vol. 71, no. 1, 23 July 1997 (1997-07-23), pages 29 - 36, XP002256079, ISSN: 0167-0115 *

Also Published As

Publication number Publication date
WO2007047577A2 (en) 2007-04-26

Similar Documents

Publication Publication Date Title
WO2004041183A3 (en) Methods of treating pulmonary fibrotic disorders
CR10627A (en) THERAPEUTIC METHODS FOR THE TREATMENT OF VASCULAR OCULAR DISORDERS WITH DII4 ANTAGONISTS
UA101309C2 (en) Activin-actrii antagonists thereof and uses for increasing red blood cell levels
BRPI0013478B8 (en) medicament comprising pde inhibitor and use of roflumilast
WO2006071274A3 (en) Leuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer’s disease
WO2007087457A3 (en) Combination therapy for the treatment of neovascular disorders
WO2006059108A3 (en) ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES
WO2005107726A3 (en) Method for the treatment of back pain
EA200400982A1 (en) METHODS OF TREATMENT OF PATIENTS SUFFERING FROM DISTURBANCE OF MOTION
MX2010009447A (en) Use of lhrh antagonists at non-castrating doses.
WO2002100352A3 (en) Nr2b receptor antagonists for the treatment or prevention of migraines
WO2007105113A3 (en) Use of crf1 receptor antagonists for preparing a drug for treating metabolic syndrome and/or obesity and/or dyslipoproteinemia
UA86621C2 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2004041272A3 (en) Use of serotonin receptor antagonists for the treatment of sleep apnea
WO2007137204A3 (en) Methods for the delivery of a beta2 agonist to induce bronchodilation and formulations for use in the same
DE602008006700D1 (en)
WO2006036770A3 (en) Combination therapy for the treatment of obesity
Kao et al. Pain Control after Total Knee Arthroplasty: Comparing Intra‐Articular Local Anesthetic Injection with Femoral Nerve Block
WO2007047372A3 (en) Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists
NO20035602D0 (en) A composition comprising a PDE-4 inhibitor and H1 receptor antagonist, as well as its use in the preparation of a medicament for the treatment of respiratory diseases.
WO2007087557A3 (en) Surface-layer protein coated microspheres and uses thereof
MXPA05010160A (en) Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases.
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
WO2008032222A3 (en) Treatment of vertigo with acetyl-l-leucine
WO2009045900A3 (en) Methods for treating or preventing diseases associated with low bone mass

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06816991

Country of ref document: EP

Kind code of ref document: A2